 |
|
Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique
Clin Mol Hepatol. 2017;23(4):316-322. Published online 2017 Aug 22 DOI: https://doi.org/10.3350/cmh.2016.0087
|
|
Citations to this article as recorded by
 Assessment of Renal Function in Egyptian HCV Patients Treated with Combination Therapy of Sofosbuvir and Daclatasvir
Hala Abd El Maguid, Ahmed Heiba, Enass El Sayed, Hazem El-Hariri, Haythem Tolba, Muhammad Abdel Ghaffar
Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 82. CrossRef Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis
Jieun Lee, Sang Bong Ahn, Sun Young Yim, Jihyun An, Dae Won Jun, Min Jung Ko, Dong Ah Park, Jeong‐Ju Yoo
Journal of Viral Hepatitis.2022; 29(7): 496. CrossRef Safety and Efficacy of Antiviral Therapy of Chronic Hepatitis C in Chronic Kidney Disease and Hemodialysis Patients
W. Fadili, A. Ait Errami, S. Zaoui, K. Elkassimi, N. ElBouhi, S. Oubaha, Z. Samlani, I. Laouad, K. Krati
European Journal of Medical and Health Sciences.2021; 3(1): 160. CrossRef Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi
Nefrología.2020; 40(1): 46. CrossRef Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment
Rasha Eletreby, Magdy El‐Serafy, Mahmoud Anees, Gamal Kasem, Marwa Salama, Reham Elkhouly, Mostafa Hamdy, Hisham Abdel Haleem, Ehab Kamal, Wael Abdel‐Razek, Rabab Salama, Mohamed Elshenawy, Ayman Shafeek, Mohamed Hassany, Manal H. El‐Sayed, Yehia El‐Shazl
Liver International.2020; 40(4): 797. CrossRef Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi
Nefrología (English Edition).2020; 40(1): 46. CrossRef Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment
Shao-Ming Chiu, Ming-Chao Tsai, Chun-Yen Lin, Chien-Hung Chen, Sheng-Nan Lu, Chao-Hung Hung, I-Shyan Sheen, Rong-Nan Chien, Chih-Lang Lin, Tsung-Hui Hu, Yu-Fan Cheng, Chao-Long Chen, Tatsuo Kanda
PLOS ONE.2020; 15(4): e0231102. CrossRef Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis
Kazumichi Abe, Hiroto Wakabayashi, Haruo Nakayama, Tomohiro Suzuki, Masahito Kuroda, Naoe Yoshida, Jun Tojo, Atsuko Kogure, Tsuyoshi Rai, Hironobu Saito, Shinji Mukai, Masashi Fujita, Manabu Hayashi, Atsushi Takahashi, Hiromasa Ohira, Ming-Lung Yu
PLOS ONE.2020; 15(12): e0243473. CrossRef Treating hepatitis C virus in dialysis patients: How, when, and why?
Javier Pagan, Marco Ladino, David Roth
Seminars in Dialysis.2019; 32(2): 152. CrossRef Sofosbuvir
Reactions Weekly.2018; 1688(1): 219. CrossRef Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic
Jessica L. Michal, Saira Rab, Manish Patel, Alison W. Kyle, Lesley S. Miller, Kirk A. Easley, Aley G. Kalapila
AIDS Research and Human Retroviruses.2018; 34(8): 690. CrossRef Renal safety after one year of sofosbuvir‐based therapy for chronic hepatitis C: A Brazilian “real‐life” study
T. Medeiros, N. F. Rosário, G. N. Saraiva, T. G. Andrade, A. A. Silva, J. R. Almeida
Journal of Clinical Pharmacy and Therapeutics.2018; 43(5): 707. CrossRef 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
Clinical and Molecular Hepatology.2018; 24(3): 169. CrossRef Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
Chih-Chin Kao, Yu-Shiuan Lin, Heng-Cheng Chu, Te-Chao Fang, Mai-Szu Wu, Yi-No Kang
Journal of Clinical Medicine.2018; 7(10): 314. CrossRef Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir
Josip Begovac, Juraj Krznarić, Nikolina Bogdanić, Loris Močibob, Šime Zekan
Medicine.2018; 97(51): e13671. CrossRef Use of sofosbuvir in chronic kidney disease: Is it necessary?
Tae Seop Lim, Sang Hoon Ahn
Clinical and Molecular Hepatology.2017; 23(4): 308. CrossRef
|